Nasopharyngeal Carcinoma
Conditions
Keywords
Surgery, Target-reduction Chemoradiotherapy, Locally Resectable Nasopharyngeal Carcinoma
Brief summary
Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined surgery could bring patients better local-regional control and lower adverse reactions.
Interventions
DRUGGemcitabine
for induction chemotherapy
DRUGCisplatin
for induction and concurrent chemotherapy
RADIATIONregular intensity-modulated radiotherapy
in active comparator arm
PROCEDUREsurgery
in experimental arm
RADIATIONTarget-reduction intensity-modulated radiotherapy
in experimental arm
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Performance Status Score 0-1 points. * Non-keratinized carcinoma of the nasopharynx (differentiated or undifferentiated, i.e., WHO type II or III) confirmed histologically and/or cytologically. * Patients with primary nasopharyngeal lesions evaluated as surgically resectable before chemotherapy, including T1 (tumor limited to nasopharynx), T2 (tumor limited to the surface of parapharyngeal space) and T3 (tumor limited to the bottom wall of sphenoid sinus or pterygoid process). Clinical stage: T1-3N1-3M0, T2-3N0M0 (Stage II-IVA) according to AJCC v8. * Patients with cervical lymph nodes evaluated as surgically resectable before chemotherapy, including cervical lymph nodes with no invasion (encasement) of the common or ICA, the epidermis, mediastinal structures, prevertebral fascia, or cervical vertebrae. * Patients with retropharyngeal lymph nodes evaluated as surgically resectable before chemotherapy, including simple RPLNs with intact capsule or RPLNs ≤ 1.5cm with mouth opening range \> 4cm. * Adequate organ function: WBC ≥ 4×10\^9 /L, NEUT ≥ 2×10\^6 /L, HGB ≥ 9 g/dL, PLT count ≥ 100×10\^9/L, TBIL ≤1.5 ULN (TBIL ≤3 ULN for patients with Gilbert Disease), ALT ≤3 ULN, AST ≤3 ULN, ALP ≤3 ULN, ALB ≥ 3 g/dL, INR or APTT≤1.5 ULN, Scr ≤1.5 ULN or Ccr ≥ 60 mL/min. * Informed Concent signed with willingness to obey the follow-up, treatment, examination and any other programs according to the research protocol.
Exclusion criteria
* Diagnosed as recurrent or distant metastatic nasopharyngeal carcinoma or together with any other malignancy. * Suffering severe cardiopathy or pulmonary dysfunction with cardiac or pulmonary function no more than grade 3. * Extensive recurrent primary tumour beyond the resectable area such as extensive invasion of the skull base or a distance from the tumour margins to the internal carotid artery of less than 0·5 cm. * Retropharyngeal lymph node involved or adjacent to primary nasopharyngeal lesions (less than 0·5 cm). * Unable to cooperate with regular follow-up due to psychological, social, domestic or geological reasons. * During pregnancy or lactation. * Other patients that the chief physician considered as illegal for this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local Regional Relapse-Free Survival (LRRFS) | 3 years | The LRRFS is evaluated and calculated from the date of random assignment until the day of first local regional relapse or until the date of the last follow-up visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) | 3 years | Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) before treatment, during treatment, after treatment. |
| Overall Survival (OS) | 3 years | The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up. |
| Progress-free survival (PFS) | 3 years | Progress-free survival is calculated from the date of randomization to the date of the first progression of any site or death or censored at the date of the last follow-up. |
| Regional Relapse-Free Survival (RRFS) | 3 years | The RRFS was defined as the duration from the date of random assignment to the date of regional relapse or censored at the date of the last follow-up. |
| Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35) | 3 years | Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35) before treatment, during treatment, after treatment. |
| Incidence of treatment related acute complications | 1 years | The proportion of patients with treatment related acute complications according to NCI-CTC5.0 criteria and RTOG criteria. |
| Incidence of treatment related late complications | 3 years | The proportion of patients with treatment related late complications according to NCI-CTC5.0 criteria and RTOG criteria. |
| Distant Metastasis-Free Survival (DMFS) | 3 years | The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit. |
Countries
China
Contacts
Primary ContactMing-yuan Chen, MD, PhD
Backup ContactRui You, MD, PhD
Outcome results
None listed